Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J T Hartmann

Showing results (11-20 of 114) with videos related to

Pageof 12
Sort By:
Der Urologe. Ausg. A|April 14, 2006
[Chemotherapy of testicular cancer]S Krege, J T Hartmann, H Rübben
World Journal of Urology|April 2, 2004
Advances in our understanding of the biology, new diagnostic approaches and recent treatment strategies for testicular germ cell cancerM Kuczyk, C Bokemeyer, J T Hartmann
Anti-Cancer Drugs|June 19, 2004
Hypersensitivity pneumonitis associated with the use of trofosfamideH-G Kopp, L Kanz, J T Hartmann
International Journal of Cancer|December 22, 1999
Platinum organ toxicity and possible prevention in patients with testicular cancerJ T Hartmann, C Kollmannsberger, L Kanz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 2000
Follow up after primary treatment: curable diseases treated non-surgicallyC Bokemeyer, C Kollmannsberger, J T Hartmann, et al.
International Journal of Cancer|December 22, 1999
Therapy-related malignancies following treatment of germ cell cancerC Kollmannsberger, J T Hartmann, L Kanz, et al.
Journal of Cancer Research and Clinical Oncology|June 10, 1998
Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignanciesC Kollmannsberger, J T Hartmann, L Kanz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2010
Myocardial infarction and other major vascular events during chemotherapy for testicular cancerK-P Dieckmann, A Gerl, J Witt, et al.
Clinical Pharmacology and Therapeutics|July 9, 2005
Leflunomide and peripheral neuropathy: a potential interaction between uracil/tegafur and leflunomideH-G Kopp, K Moerike, L Kanz, et al.
European Journal of Cancer (Oxford, England : 1990)|December 7, 2007
Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapyC Sammler, J Beyer, C Bokemeyer, et al.
Pageof 12

Showing results (11-20 of 114) with videos related to

Sort By:
Pageof 12
Der Urologe. Ausg. A|April 14, 2006
[Chemotherapy of testicular cancer]S Krege, J T Hartmann, H Rübben
World Journal of Urology|April 2, 2004
Advances in our understanding of the biology, new diagnostic approaches and recent treatment strategies for testicular germ cell cancerM Kuczyk, C Bokemeyer, J T Hartmann
Anti-Cancer Drugs|June 19, 2004
Hypersensitivity pneumonitis associated with the use of trofosfamideH-G Kopp, L Kanz, J T Hartmann
International Journal of Cancer|December 22, 1999
Platinum organ toxicity and possible prevention in patients with testicular cancerJ T Hartmann, C Kollmannsberger, L Kanz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 2000
Follow up after primary treatment: curable diseases treated non-surgicallyC Bokemeyer, C Kollmannsberger, J T Hartmann, et al.
International Journal of Cancer|December 22, 1999
Therapy-related malignancies following treatment of germ cell cancerC Kollmannsberger, J T Hartmann, L Kanz, et al.
Journal of Cancer Research and Clinical Oncology|June 10, 1998
Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignanciesC Kollmannsberger, J T Hartmann, L Kanz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2010
Myocardial infarction and other major vascular events during chemotherapy for testicular cancerK-P Dieckmann, A Gerl, J Witt, et al.
Clinical Pharmacology and Therapeutics|July 9, 2005
Leflunomide and peripheral neuropathy: a potential interaction between uracil/tegafur and leflunomideH-G Kopp, K Moerike, L Kanz, et al.
European Journal of Cancer (Oxford, England : 1990)|December 7, 2007
Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapyC Sammler, J Beyer, C Bokemeyer, et al.
Pageof 12